KEAP1 and Parkinson disease: Additionally, in 6-OHDA-induced PD models, impaired CMA, caused by LAMP2 knockdown or treatment with bafilomycin A1, hinders the degradation of Keap1, thereby leading to the inactivation of Nrf2.